SCHEMBL3131963

SCHEMBL3131963

c1ccc(SCOCSc2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
MAPK1 P28482 1/20 0.57
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
FFAR1 O14842 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
MGLL Q99685 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP2C9 P11712 1/20 0.39
HIF1A Q16665 1/20 0.39
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
TSHR P16473 1/20 0.38
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18911565 1.00 ALDH1A1 (0.57) ALDH1A1MAPK1MAOAMAOBFFAR1
SCHEMBL23618758 0.85 ALDH1A1 (0.48) ALDH1A1MAPK1MAOAMAOBFFAR1
SCHEMBL16893596 0.85 ALDH1A1 (0.48) ALDH1A1MAPK1MAOAMAOBFFAR1
SCHEMBL29185026 0.80 FFAR1 (0.55) ALDH1A1MAPK1FFAR1SMN1; SMN2MAPT
SCHEMBL8873004 0.79 ALDH1A1 (0.52) ALDH1A1MAPK1MAOAMAOBFFAR1
SCHEMBL942119 0.79 ALDH1A1 (0.52) ALDH1A1MAPK1MAOAMAOBFFAR1
SCHEMBL6536310 0.77 ALDH1A1 (0.50) ALDH1A1MAPK1MAOAMAOBFFAR1
SCHEMBL10911324 0.77 ALDH1A1 (0.50) ALDH1A1MAPK1FFAR1NPC1DRD2
SCHEMBL12110732 0.77 ALDH1A1 (0.50) ALDH1A1MAPK1MAOAMAOBFFAR1
Fluoride SCHEMBL1336321 0.77 ALDH1A1 (0.50) ALDH1A1MAPK1MAOAMAOBFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2758414-B1 RUTHENIUM CONTAINING HYDROSILYLATION CATALYSTS AND COMPOSITIONS CONTAINING THE CATALYSTS DOW SILICONES CORP (US) 2018-11-21 EP claimed
US-9480977-B2 Ruthenium containing hydrosilylation catalysts and compositions containing the catalysts DOW CORNING CORPORATION (US) 2016-11-01 US claimed
US-20140275329-A1 Ruthenium Containing Hydrosilylation Catalysts And Compositions Containing The Catalysts DOW SILICONES CORPORATION 2014-09-18 US claimed
EP-2758414-A2 RUTHENIUM CONTAINING HYDROSILYLATION CATALYSTS AND COMPOSITIONS CONTAINING THE CATALYSTS Dow Corning Corporation (US) 2014-07-30 EP claimed
WO-2013043787-A2 RUTHENIUM CONTAINING HYDROSILYLATION CATALYSTS AND COMPOSITIONS CONTAINING THE CATALYSTS DOW CORNING CORPORATION (US) 2013-03-28 WO claimed
US-12551570-B2 Compounds comprising cleavable linker and uses thereof INTOCELL, INC. (KR) 2026-02-17 US disclosed
EP-4049996-B1 GLYCOSIDE COMPOUND, AMIDITE COMPOUND, AND PRODUCTION METHOD FOR POLYNUCLEOTIDE USING SAID COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2026-01-07 EP disclosed
US-12509481-B2 Glycoside compound, amidite compound, and production method for polynucleotide using said compounds SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2025-12-30 US disclosed
US-12509483-B2 Method for producing nucleic acid oligomers SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2025-12-30 US disclosed
US-12479927-B2 Compounds comprising cleavable linker and uses thereof INTOCELL, INC. (KR) 2025-11-25 US disclosed
US-20250213712-A1 ANTIBODY DRUG CONJUGATES COMPRISING CAMPTOTHECIN DERIVATIVES AND USES THEREOF INTOCELL, INC. (KR) 2025-07-03 US disclosed
US-12274898-B2 Substituted benzodiazepines as antibody-drug conjugates INTOCELL, INC. (KR) 2025-04-15 US disclosed
EP-0194554-B1 PROCESS FOR PRODUCTION OF OXIME DERIVATIVES NIPPON ZEON CO., LTD. (JP) 1993-09-01 EP disclosed
US-4906768-A Process for production of oxime derivatives NIPPON ZEON CO., LTD. (JP) 1990-03-06 US disclosed
WO-1988001619-A1 1'-METHYL-BETA-LACTAM COMPOUNDS AND THEIR PRODUCTION SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1988-03-10 WO disclosed
EP-0119457-B1 AGENT FOR REGULATING THE GROWTH OF PLANTS BAYER AG (DE) 1986-12-30 EP disclosed
EP-0194554-A2 Process for production of oxime derivatives NIPPON ZEON CO., LTD. (JP) 1986-09-17 EP disclosed
EP-0052799-B1 D-HOMO STEROIDS, THEIR UTILIZATION AND PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1985-01-30 EP disclosed
US-4361578-A ANTIANDROGENS ALIG L 1982-11-30 US disclosed
EP-0052799-A1 D-homo steroids, their utilization and preparation and pharmaceutical compositions containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1982-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509483-B2 Method for producing nucleic acid oligomers POLM, RNGTT, POLRMT ALDH1A1 4313/4885MAPK1 4470/4885MAOA 3925/4885
US-20250213712-A1 ANTIBODY DRUG CONJUGATES COMPRISING CAMPTOTHECIN DERIVATIVES AND USES THEREOF CD47, TOP2A, SSB ALDH1A1 2732/4885MAPK1 3141/4885MAOA 3461/4885
US-12551570-B2 Compounds comprising cleavable linker and uses thereof FCGR2A, FCGR3B, FCGR1A ALDH1A1 4586/4885MAPK1 3340/4885MAOA 2177/4885
US-12479927-B2 Compounds comprising cleavable linker and uses thereof VIP, ANTXR2, TNFRSF9 ALDH1A1 4822/4885MAPK1 2334/4885MAOA 1804/4885
US-12509481-B2 Glycoside compound, amidite compound, and production method for polynucleotide using said compounds RNMT, NOP10, PNP ALDH1A1 4503/4885MAPK1 1125/4885MAOA 2062/4885
US-12274898-B2 Substituted benzodiazepines as antibody-drug conjugates GABRA3, GABRA6, GABRA4 ALDH1A1 207/4885MAPK1 4089/4885MAOA 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.